AMA supports FDA’s changes to prescription opioids labels
AMA welcomes FDA including tapering guidance on prescription opioid labels, changes mirror points that AMA has emphasized in efforts to end the opioid epidemic.
AMA applauds congressional action on prescription drug transparency
The AMA believes in transparency in prescription drug pricing, and we are pleased the House Ways & Means Committee moved the issue forward.
AMA: New Jersey shows leadership to help end opioid epidemic
The AMA commended NJ Gov. Murphy and state Human Services Commissioner Johnson for helping end barriers to treatment for patients with opioid use disorder.
AMA applauds House leaders for proposed improvements to the ACA
The AMA commends House leadership on efforts to strengthen the ACA. The task now is to build on what has been shown to work and to make improvement as needed.
AMA statement on Title X gag rule and funding restrictions
This rule interferes with and imposes restrictions on the patient-physician relationship.
AMA applauds efforts in NC to reach residents with prediabetes
New $5 million investment by BCBS of North Carolina to fund partnership between NC State University and NC Division of Public Health aimed at type 2 diabetes.
AMA: FDA action on OTC naloxone will save people from overdoses
The AMA applauds the FDA and Commissioner Gottlieb for action to provide labeling that would allow for OTC availability of naloxone.
Membership Moves Medicine™
- Free access to JAMA Network™ and CME
- Save hundreds on insurance
- Fight for physicians and patient rights
AMA member physicians get a 35% discount on own-specialty disability insurance premiums.Calculate Your Quote Now